Target Deliver of Epigallocatechin Gallate by Hemo

Traumatic hemorrhage remains the leading cause of combat related preventable deaths due to lack of necessary innovation to stanch non-compressible blood loss in the field, where soldiers are required to rely on limited resources for extend periods of time until evacuation can take place. Combat casualty care options are limited to compact, portable, easily administered therapies. The mounting rise in infectious complication after combat casualty wounds also presents an immediate health risk to after-care of military personnel and impacts the healing process after injury. Infectious complications in combat wounds result in extensive debridement in amputations resulting in further loss in function of limbs. A novel treatment alternative that would stanch hemorrhage and preemptively combat a broad spectrum of pathogens would be superior to what is currently available in both civilian and military medicine.